Shares Issued
As at 5 June 2020, the number of shares in issue was 433,636,255.
Significant Shareholders
As at 5 June 2020
| Shareholder | Number | Ordinary Shares % |
|---|---|---|
| Craig Auringer | 23,837,250 | 5.50 |
| Samantha Bauer | 17,996,487 | 4.15 |
| Mark Hawtin | 12,668,570 | 2.92 |
Director Shareholdings
As at 5 June 2020
| Director | Number | Ordinary Shares % |
|---|---|---|
| Alexis Sandler | 75,090,685 | 17.32 |
| Dr Vladislav Sandler | 41,544,677 | 9.58 |
| Peter Redmond | 5,596,270 | 1.29 |
Shares Not In Public Hands
Insofar as it is aware, as at 5 June 2020, 50.01% of the Company’s securities were not in public hands.
UK City Code On Takeovers And Mergers
The Company is subject to the provisions of the City Code on Takeovers and Mergers.
Shareholder Circulars
| 12 May 2020 | Notice of AGM to be held on 4 June 2020 |
As the 2020 AGM was held as a closed meeting due to COVID-19 public health restrictions on travel and meetings, shareholders were invited to submit questions to the directors relating to the business of the AGM in advance. While the company continues to engage with shareholders, no such questions were formally submitted. An operational update was published as part of the announcement of AGM results. The Company looks forward to re-establishing full shareholder engagement as soon as practical, and continues to publish relevant news promptly.
Financial Reports
Annual and Half Year Reports, together with historical AGM notices and proxy voting forms, may be found here: Annual and Half Year Reports.
Other Exchanges And Trading Platforms
Hemogenyx Pharmaceuticals plc has not applied or agreed to have any of it securities admitted or traded on any other exchanges or trading platforms.